NVO Reports Strong Phase III Diabetes Data for Children & Adolescents
24/4 18:44
Novo Nordisk reports phase III teen study success for oral semaglutide, showing strong HbA1c reduction and paving the way for the first oral GLP-1 for youth....
|
|
|
24/4 18:44
Novo Nordisk reports phase III teen study success for oral semaglutide, showing strong HbA1c reduction and paving the way for the first oral GLP-1 for youth....